<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753246</url>
  </required_header>
  <id_info>
    <org_study_id>OSAG101-BSA05</org_study_id>
    <nct_id>NCT00753246</nct_id>
  </id_info>
  <brief_title>Nimotuzumab in Adults With Glioblastoma Multiforma</brief_title>
  <official_title>Phase-III Study of Standard Radiotherapy Plus Concomitant and Adjuvant OSAG 101 (Theraloc®) Plus Temozolomide vs. Standard Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Patient With Newly Diagnosed, Histologically Confirmed Glioblastoma Multiforme Grade IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncoscience AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Neurological Clinic, Knappschaftskrankenhaus Bochum-Langendreer, Bochum, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bonn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dep. of Neurosurgery and Policlinic, University Hospital, Dresden, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kiel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. von Haunersches Children's Medical Hospital, University of Munich, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universität Tübingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oncoscience AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determination of efficiency of nimotuzumab in adults with glioblastoma multiforma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the present study is a comparison of treatment of patients with newly
      diagnosed glioblastoma multiforme grade IV. Patients will be randomized in one of two arms
      when included. Patients randomly assigned to arm A will receive Nimotuzumab (OSAG 101) plus
      Temozolomide concomitant with standard radiotherapy. Patients randomised in arm B will
      receive standard radiotherapy plus Temozolomide treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free interval determined by MRI</measure>
    <time_frame>week 12, 24, 36, 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival Time to reintervention Response rate according to RECIST criteria Toxicity according to CTC criteria Symptom control Quality of life</measure>
    <time_frame>week 12, 24, 36, 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Adults With Glioblastoma Multiforma</condition>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>adults with TMZ, RT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adults with TMZ, RT, nimotuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nimotuzumab</intervention_name>
    <description>monoclonal antibody</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient signed informed consent

          -  Newly diagnosed, histologically confirmed glioblastoma multiforme grade IV

          -  Condition is measurable by MRI in at least one dimension

          -  Age 18-70

          -  Karnofsky-Index &gt; 40

          -  Treatment in a study center

          -  Female patients with a childbearing potential must have a negative pregnancy test
             within one week before inclusion in the trial. Those female and male patients admitted
             in the study must use a reliable method of contraception.

          -  Adequate haematological, renal and hepatic function:

               -  Leucocytes &gt;2.0x10^9/l

               -  Hb&gt; 10g/dl

               -  Billirubin total &lt; 2.5x upper limit of normal (ULN)

               -  Creatinin i.S. &lt; 1.5x ULN

               -  AST (GOT)/ALT (GPT) &lt; 5x ULN

        Exclusion Criteria:

          -  Patients with history of anaphylactic reaction to murine or humanized antibody

          -  Patients with evidence second malignancy

          -  Patients who are pregnant or patients who refused adequate contraceptive precaution
             (female and male) during the trial

          -  Pregnancy and lactation

          -  Other conditions considered by investigators as sound reasons for disqualification
             from enrolment into the study such as: potential non compliance with protocol
             requirement

          -  No MRI for tumour evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manfred Westphal, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hamburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dep. Neurosurgery, Univ. Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <last_update_submitted>November 30, 2012</last_update_submitted>
  <last_update_submitted_qc>November 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2012</last_update_posted>
  <responsible_party>
    <name_title>Oncoscience AG</name_title>
  </responsible_party>
  <keyword>glioblastoma multiforma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

